咪达普利治疗老年性高血压的疗效及安全性观察  

Efficacy and safety observation of imidapril in the treatment of senile hypertension

作　　者：宋广普 

机构地区：[1]宝鸡市第二人民医院,陕西宝鸡721000

出　　处：《临床医学研究与实践》2018年第2期28-29,共2页Clinical Research and Practice

摘　　要：目的探讨咪达普利对于老年性高血压的临床治疗效果及其安全性。方法选择我院2015年2月至2017年2月纳入的原发性老年高血压患者160例,随机分为试验组与对照组,每组80例。试验组患者给予咪达普利治疗,对照组患者给予卡托普利治疗。观察比较两组患者的治疗效果、血压、血常规、尿常规及肝、肾功能生化指标水平变化及不良反应发生情况。结果试验组临床治疗总有效率为86.25%,显著高于对照组的68.75%(P<0.05);治疗1、2、4周后,两组收缩压与舒张压均低于治疗前,且试验组低于对照组(P<0.05);两组患者治疗前、后的心率、血常规、尿常规及相关生化指标水平变化均不明显,差异不具有统计学意义(P>0.05);试验组不良反应总发生率显著低于对照组(P<0.05)。结论咪达普利具有控制血压效果明显、保护患者机体肝肾功能、不良反应少、副作用小等特点,值得临床推广使用。Objective To investigate the efficacy and safety of imidapril in the treatment of senile hypertension. MethodsA total of 160 patients with essential hypertension in our hospital from February 2015 to February 2017 were randomlydivided into experimental group and control group, with 80 cases in each group. Patients in the experimental group weretreated with imidapril, and patients in the control group were treated with captopril. The effects of treatment, bloodpressure, blood routine, urine routine, liver and kidney function biochemical indexes and adverse reactions were observedand compared between the two groups. Results The total effective rate of clinical treatment in the experimental group was86.25%, which was significantly higher than 68.75% in the control group（P〈0.05）. After 1,2 and 4 weeks of treatment, thesystolic and diastolic blood pressure in both groups were lower than those before treatment, and those in the experimentalgroup was lower than the control group（P〈0.05）. Before and after treatment, the heart rate, blood routine, urine routine andrelated biochemical indicators of the two groups were not significantly different（P〉0.05）. The total incidence of adversereactions in the experimental group was significantly lower than that in the control group（P〈0.05）. Conclusion Imidapril inthe treatment of senile hypertension has obvious effect of controlling blood pressure, it can protect the liver and kidneyfunction of patients, with less adverse reactions and side effect, which is worthy of clinical promotion.

关 键 词：高血压 安全性 卡托普利 咪达普利 

分 类 号：R544.1[医药卫生—心血管疾病]